AN OPEN-LABEL, RANDOMIZED PHASE II STUDY ON TRABECTEDIN AND BEVACIZUMAB WITH OR WITHOUT CARBOPLATIN IN PARTIALLY PLATINUM-SENSITIVE (PPS) OVARIAN CANCER

被引：0
|
作者：
Gerardi, C. [1 ]
Floriani, I. [1 ]
Biagioli, E. [1 ]
D'Incalci, M. [1 ]
Fossati, R. [1 ]
Colombo, N. [2 ]
机构：
[1] IRCCS Ist Ric Farmacol Mario Negri Milano, Milan, Italy
[2] Univ Milano Bicocca, Dipartimento Sci Chirurg, Milan, Italy
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2014年 / 24卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCSM-1249
引用
收藏
页码：455 / 456
页数：2
相关论文
共 50 条
  • [1] RANDOMIZED, NON-COMPARATIVE, PHASE II TRIAL OF BEVACIZUMAB AND TRABECTEDIN WITH OR WITHOUT CARBOPLATIN IN PARTIALLY PLATINUM-SENSITIVE OVARIAN CANCER (ROC) WOMEN
    Colombo, N.
    Nicoletto, M. O.
    Lissoni, A.
    Scambia, G.
    Tognon, G.
    Negri, E.
    Galli, F.
    Biagioli, E.
    Rulli, E.
    Fossati, R.
    D'Incalci, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 277 - 277
  • [2] RANDOMIZED, NON-COMPARATIVE, PHASE II TRIAL OF BEVACIZUMAB AND TRABECTEDIN WITH OR WITHOUT CARBOPLATIN IN PARTIALLY PLATINUM-SENSITIVE OVARIAN CANCER (ROC) WOMEN
    Colombo, N.
    Nicoletto, M. O.
    Lissoni, A.
    Scambia, G.
    Tognon, G.
    Negri, E.
    Galli, F.
    Biagioli, E.
    Rulli, E.
    Fossati, R.
    D'Incalci, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1471 - 1471
  • [3] Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer
    Nicoletta Colombo
    Eleonora Zaccarelli
    Alessandra Baldoni
    Simona Frezzini
    Giovanni Scambia
    Eleonora Palluzzi
    Germana Tognon
    Andrea A. Lissoni
    Daniela Rubino
    Annamaria Ferrero
    Gabriella Farina
    Emanuele Negri
    Angela Pesenti Gritti
    Francesca Galli
    Elena Biagioli
    Eliana Rulli
    Davide Poli
    Chiara Gerardi
    Valter Torri
    Roldano Fossati
    Maurizio D‘Incalci
    British Journal of Cancer, 2019, 121 : 744 - 750
  • [4] Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer
    Colombo, Nicoletta
    Zaccarelli, Eleonora
    Baldoni, Alessandra
    Frezzini, Simona
    Scambia, Giovanni
    Palluzzi, Eleonora
    Tognon, Germana
    Lissoni, Andrea A.
    Rubino, Daniela
    Ferrero, Annamaria
    Farina, Gabriella
    Negri, Emanuele
    Gritti, Angela Pesenti
    Galli, Francesca
    Biagioli, Elena
    Rulli, Eliana
    Poli, Davide
    Gerardi, Chiara
    Torri, Valter
    Fossati, Roldano
    D'Incalci, Maurizio
    BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 744 - 750
  • [5] A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer
    Eisenhauer, Eric L.
    Zanagnolo, Vanna
    Cohn, David E.
    Salani, Ritu
    O'Malley, David M.
    Sutton, Gregory
    Callahan, Michael J.
    Cobb, Bobbi
    Fowler, Jeffrey M.
    Copeland, Larry J.
    GYNECOLOGIC ONCOLOGY, 2014, 134 (02) : 262 - 266
  • [6] A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer
    Eisenhauer, E.
    Zanagnolo, V.
    Cohn, D.
    Salani, R.
    O'Malley, D.
    Sutton, G.
    Cobb, B.
    Vaughan, M.
    Fowler, J.
    Copeland, L.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S31 - S31
  • [7] Phase II Study of Pegylated Liposomal Doxorubicin and Carboplatin in Patients With Platinum-Sensitive and Partially Platinum-Sensitive Metastatic Ovarian Cancer
    Rapoport, B. L.
    Vorobiof, D. A.
    Slabber, C.
    Alberts, A. S.
    Hlophe, H. S.
    Mohammed, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (06) : 1137 - 1141
  • [8] GLORIOSA: A randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
    O'Malley, David M.
    Myers, Tashanna K. N.
    Zamagni, Claudio
    Diver, Elisabeth
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Phase II Study of Carboplatin and Pemetrexed for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
    Matulonis, Ursula A.
    Horowitz, Neil S.
    Campos, Susana M.
    Lee, Hang
    Lee, Julie
    Krasner, Carolyn N.
    Berlin, Suzanne
    Roche, Maria R.
    Duska, Linda R.
    Pereira, Lauren
    Kendall, Deborah
    Penson, Richard T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) : 5761 - 5766
  • [10] Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer
    Matulonis, U.
    Richard, P.
    Campos, S.
    Bryan, J.
    Lee, J.
    Kendal, D.
    Krasner, C.
    Berlin, S.
    Roche, M.
    Duska, L.
    Pereira, L.
    Horowitz, N.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S23 - S24
12345